Novartis CEO plans 80+ submissions for drug approvals through 2022

Novartis is planning more than 80 major submissions to regulators for drug approvals from 2020-2022 in the United States, Europe, Japan and China, Chief Executive Vas Narasimhan said on Thursday ahead of a meeting with analysts and investors.

from Reuters: Health News https://ift.tt/389ezd1
via IFTTT